Shouyao Holdings News

Here's Why We're Not At All Concerned With Shouyao Holdings (Beijing)'s (SHSE:688197) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a ne

Simply Wall StApr 30 10:23

First Pharmaceutical Holdings (688197.SH) announced 2023 annual results with a net loss of 186 million yuan

First Pharmaceutical Holdings (688197.SH) released its 2023 annual performance report. During the reporting period, the company achieved an operating income of 5...

Zhitong FinanceApr 28 15:57

First Pharmaceutical Holdings (688197): Third-generation ALK phase III clinical trials have begun to enroll RET inhibitors and ASCO will disclose key phase II data

Incident: The company released its 2023 annual report. In 2023, it achieved operating income of 0.5 billion yuan (+186.18%), net profit to mother of 190 million yuan, and net profit of non-return to mother of 200 million yuan. Q1 2024

西南證券Apr 28 00:00

The A-share innovative drug sector boosted in early trading, and First Pharmaceutical Holdings rose more than 8%

Gelonghui, March 27 | First Pharmaceutical Holdings rose more than 8%, followed by Hokuriku Pharmaceutical, Osecon, Eddy Pharmaceutical, Changshan Pharmaceutical, and Hanyu Pharmaceutical.

Gelonghui FinanceMar 27 09:51

First Pharmaceutical Holdings (688197.SH): 1.487,200 restricted shares banned on March 25

On March 15, Gelonghui Holdings (688197.SH) announced that the total number of shares in circulation in the company's current stock listing was 1.487,200 shares. The stock listing and circulation date is March 25, 2024.

Gelonghui FinanceMar 15 19:03

Express News | First Pharmaceutical Holdings: The company's core self-developed products are all in the R&D stage, and no products have been launched to contribute sales revenue

BreakingsMar 14 18:25

Express News | 93 science and technology innovation board companies announced their 2023 performance reports. Hangya Technology's net profit increased the most

BreakingsFeb 23 10:30

First Pharmaceutical Holdings-U (688197) 2023 Annual Performance Report Review: Product Development Promotes Smoothly, Authorization Revenue Increased Significantly

Matters: The company released the 2023 annual results report. The total revenue for 2023 is estimated to be 5.2292 million yuan, an increase of 186.19% over the previous year; net profit due to mother is estimated to be -184 million yuan in 2023, deducted

華創證券Feb 20 15:06

CEO Wenjun Li, Shouyao Holdings (Beijing) Co., LTD.'s (SHSE:688197) Largest Shareholder Sees Value of Holdings Go Down 20% After Recent Drop

Key Insights Shouyao Holdings (Beijing)'s significant insider ownership suggests inherent interests in company's expansion Wenjun Li owns 52% of the company 11% of Shouyao Holdings (Beijing) is h

Simply Wall StFeb 2 06:53

First Pharmaceutical Holdings (688197.SH) Performance Report: Net loss of 184 million yuan in 2023

Gelonghui, January 30丨First Pharmaceutical Holdings (688197.SH) announced its 2023 annual results report. During the reporting period, the company achieved total operating income of 5,2292 million yuan, an increase of 186.19% year on year; R&D expenses of 201.206 million yuan, up 0.89% year on year; net profit attributable to owners of the parent company - 18.38443 million yuan, a year-on-year increase of 10.275 million yuan; net profit attributable to owners of the parent company after deducting non-recurring profit and loss of 197.22.5 million yuan.

Gelonghui FinanceJan 30 19:24

Shouyao Receives Hospital Approval for the Trial of Lung Cancer Drug

Pharmaceutical company Shouyao Holdings (Beijing) (SHA:688197) received approval from the Cancer Hospital of the University of Chinese Academy of Sciences' ethics committee to hold the phase III clini

MT NewswiresDec 26, 2023 18:06

First Pharmaceutical Holdings (688197.SH): The critical phase III clinical trial of the third-generation ALK kinase inhibitor SY-3505 obtained an ethical approval report

Gelonghui, December 25|First Pharmaceutical Holdings (688197.SH) announced that the company recently received an approval report issued by the Cancer Hospital Ethics Committee of the Chinese Academy of Medical Sciences. After a vote, the hospital's ethics committee approved the approval application for “a randomized, controlled, multi-center phase III clinical trial to evaluate the efficacy and safety of CT-3505 capsules compared to crixotinib capsules in ALK-positive non-small cell lung cancer patients” (Note: Since 2016, the company has uniformly used “SY” to name its own research pipeline, etc. You need to use CT-350 when

Gelonghui FinanceDec 25, 2023 17:42

The innovative drug sector fluctuated and rose higher, and First Pharmaceutical Holdings rose more than 10%

Gelonghui, November 15 | The innovative pharmaceutical sector fluctuated higher. First Pharmaceutical Holdings and Furui Co., Ltd. rose more than 10%, while Tonghua Jinma, Mengke Pharmaceutical, Eddy Pharmaceutical, and Sansheng Guojian had the highest gains. The Tianfeng Securities Research Report points out that the profits and inventories of the innovative drug industry have been declining for a long time. The overseas austerity cycle is close to the top, and the global GLP-1 small molecule related pipelines have entered the middle to late clinical stages one after another, catalyzing the rise in popularity of the innovative drug industry chain.

Gelonghui FinanceNov 15, 2023 13:36

First Pharmaceutical Holdings (688197.SH) announced the first three quarter results, with a net loss of 136 million yuan

First Pharmaceutical Holdings (688197.SH) released its report for the first three quarters of 2023, and the company's operating income was 500.00...

Zhitong FinanceOct 30, 2023 17:33

Companies Like Shouyao Holdings (Beijing) (SHSE:688197) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a ne

Simply Wall StOct 19, 2023 14:13

First Pharmaceutical Holdings (688197.SH)'s 1,431,400 restricted shares will be listed and distributed on September 27

First Pharmaceutical Holdings (688197.SH) announced that the number of restricted shares currently listed and in circulation by the company is 1,461,400...

Zhitong FinanceSep 18, 2023 19:09

First Pharmaceutical Holdings (688197): SY3505 Key Phase II has begun to be joined and is progressing rapidly in the research pipeline

Incident: The company released its semi-annual report for 2023. In the first half of 2023, it achieved operating income of 0.5 billion yuan (+180.1%) and net profit of 90 million yuan. Achieved operating income of 0.0 in the second quarter of 2023

西南證券Aug 31, 2023 00:00

Biological vaccine stocks fell, Wantai Biotech fell to a halt

Gelonghui, August 25 | Wantai Biotech fell to a halt, followed by Shouyao Holdings, Baili Tianheng, Watson Biotech, Junshi Biotech, and Cansino.

Gelonghui FinanceAug 25, 2023 09:48

First Pharmaceutical Holdings (688197.SH): Net loss of 93.13,900 yuan in the first half of the year

Glonghui, August 21: First Pharmaceutical Holdings (688197.SH) announced its 2023 semi-annual report. During the reporting period, it achieved operating income of 5 million yuan, an increase of 180.08% over the previous year; net profit attributable to shareholders of listed companies - 93.13,900 yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 94.878 million yuan; basic earnings per share - 0.63 yuan.

Gelonghui FinanceAug 21, 2023 18:12

Shouyao Holdings (Beijing) Co., LTD.'s (SHSE:688197) Largest Shareholder, CEO Wenjun Li Sees Holdings Value Fall by 6.5% Following Recent Drop

Key Insights Insiders appear to have a vested interest in Shouyao Holdings (Beijing)'s growth, as seen by their sizeable ownership Wenjun Li owns 52% of the company 12% of Shouyao Holdings (Beiji

Simply Wall StAug 18, 2023 06:12